Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2006;8 Suppl 1(Suppl 1):S4-S10.

Magnetic resonance imaging and spectroscopy of prostate cancer

Peter R Carroll, Fergus V Coakley, John Kurhanewicz

Magnetic resonance imaging and spectroscopy of prostate cancer

Peter R Carroll et al. Rev Urol. 2006.

Abstract

Magnetic resonance imaging may improve the staging of prostate cancer compared with clinical evaluation alone, computerized tomography, or transrectal ultrasound, and it allows simultaneous and detailed evaluation of prostatic, periprostatic, and pelvic anatomy. Endorectal magnetic resonance imaging and magnetic resonance spectroscopic imaging (endoMRI/MRSI) allow better visualization of the zonal anatomy of the prostate and better delineation of tumor location, volume, and extent (stage). Metabolic criteria used to identify and localize prostate cancer with endoMRI/MRSI have been standardized, thus improving the accuracy of the examination and limiting interobserver variations in interpretation. Evidence is now emerging that endoMRI/MRSI may also be helpful in assessing response to prostate cancer treatment, most commonly with radiation and/or androgen-deprivation therapy.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Normal prostate gland, endorectal MRI, axial image. PZ, peripheral zone; TZ, transition zone.
Figure 2
Figure 2
Normal prostate gland, endorectal MRI, coronal image.
Figure 3
Figure 3
Left peripheral zone cancer (Ca) depicted on endorectal MRI, axial image.
Figure 4
Figure 4
Combined magnetic resonance imaging, diffusion tensor imaging, and 3-dimensional magnetic resonance spectroscopic imaging (MRSI) of the prostate at 1.5 tesla. A. Axial T2-weighted image and 3-dimensional MRSI spectral grid. The arrows indicate a region of prostate cancer. B. Corresponding 3-dimensional MRSI spectral array, showing the presence of an aggressive-appearing tumor (very elevated choline and reduced citrate) on the left side of the gland (right side of the image). C. Image of the mean diffusional coefficient of water demonstrates a region of prostate cancer (arrows) in the same location as the T2-weighted image and MRSI. D. Representative spectra taken from the region of healthy prostate tissue and prostate cancer. PPM, parts per million.
Figure 5
Figure 5
Gross extracapsular extension (ECE) of prostate cancer, depicted on endorectal MRI, axial image.
See this image and copyright information in PMC

References

    1. Jemal A, Murray T, Ward E, et al. Cancer statistics, 2005. CA Cancer J Clin. 2005;55:10–30. - PubMed
    1. Cooperberg MR, Lubeck DP, Mehta SS, et al. Time trends in clinical risk stratification for prostate cancer: implications for outcomes (data from CaPSURE) J Urol. 2003;170:S21–25. - PubMed
    1. Cooperberg MR, Moul JW, Carroll PR. The changing face of prostate cancer. J Clin Oncol. 2005;23:8146–8151. - PubMed
    1. Purohit RS, Shinohara K, Meng MV, et al. Imaging clinically localized prostate cancer. Urol Clin North Am. 2003;30:279–293. - PubMed
    1. Wolf JS , Jr, Cher M, Dall’era M, et al. The use and accuracy of cross-sectional imaging and fine needle aspiration cytology for detection of pelvic lymph node metastases before radical prostatectomy. J Urol. 1995;153:993–999. - PubMed

LinkOut - more resources